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Abstract
Background: Hemodynamic monitoring is very important in critically ill patients with shock or acute respiratory
distress syndrome(ARDS). The PiCCO (Pulse index Contour Continuous Cardiac Output, Pulsion Medical Systems,
Germany) system has been developed and used in critical care settings for several years. However, its impact on
clinical outcomes remains unknown.
Methods/design: The study is a randomized controlled multi-center trial. A total of 708 patients with ARDS, septic
shock or both will be included from January 2012 to January 2014. Subjects will be randomized to receive PiCCO
monitoring or not. Our primary end point is 30-day mortality, and secondary outcome measures include ICU length
of stay, days on mechanical ventilation, days of vasoactive agent support, ICU-free survival days during a 30-day
period, mechanical-ventilation-free survival days during a 30-day period, and maximum SOFA score during the first
7 days.
Discussion: We investigate whether the use of PiCCO monitoring will improve patient outcomes in critically ill
patients with ARDS or septic shock. This will provide additional data on hemodynamic monitoring and help
clinicians to make decisions on the use of PiCCO.
Trial registration: www.clinicaltrials.gov NCT01526382
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Background
Hemodynamic monitoring and the associated fluid ther-
apy are of critical importance in the management of
critically ill patients. The optimization of fluid status
remains a challenge in critical care settings because
fluid overload will lead to organ edema and an ensuing
increase in mortality [1,2], whereas inadequate circulat-
ing volume will result in insufficient perfusion pressure
and oxygen delivery. Therefore, monitoring the fluid
status of critically ill patients is very important. Recent
decades have witnessed rapid advances in fluid monitor-
ing techniques. Pulmonary artery catheters have been
widely used for more than five decades, but unfortu-
nately their usefulness in improving patient outcomes
seems disappointing [3]. The PiCCO system (Pulse
index Contour Continuous Cardiac Output, Pulsion
Medical Systems, Germany) incorporates a transpul-
monary thermodilution technique (TPTD) and continu-
ous pulse contour analysis. It is a minimally invasive
technique, which gives beat-by-beat monitoring of cardiac
output, and can provide accurate information on volume
status and pulmonary edema. Furthermore, the PiCCO
monitor is an ‘all-inclusive’ device, which provides a full
picture of a patient’s hemodynamic status, including
vascular tone, preload, and cardiac function [4]. However,
clinical studies investigating the usefulness of the PiCCO
system have mainly focused on intermediate physiological
parameters, such as fluid responsiveness, oxygenation and
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pulmonary edema, [5,6], and only a few studies have
investigated clinical outcomes of patients managed using
a PiCCO monitor [7,8]. Although these studies have
promising results, the link between its use and clinical
outcomes (for example mortality, length of stay in an ICU,
duration of mechanical ventilation) is largely unknown.
Patients with acute respiratory distress syndrome
(ARDS) are characterized by increased pulmonary
extravascular lung water (EVLW), and may potentially
benefit from EVLW monitoring. Simmons et al. [9]
noticed that a more negative fluid balance in ARDS
patients was associated with improved survival. More
recently, numerous studies have demonstrated that ele-
vated EVLW is associated with an increased mortality
rate [10,11]. A recent meta-analysis by our group also
supports this notion [12]. Thus, management algo-
rithms aiming to optimize the extravascular lung water
index (EVLWI) are assumed to be beneficial to this
group of patients. The other disease entity that is com-
monly encountered in ICUs is septic shock. This group
of patients usually receives infusions of large amounts
of fluid during theinitial period to maintain an adequate
perfusion pressure. Early goal-directed therapy (EGDT),
as proposed by Rivers, is a clinically useful bundle to
guide fluid therapy [13]. However, it is not without criti-
cism and the definition of appropriate fluid treatment is
still open to debate for this group of patients [14,15].
In this randomized controlled trial, we aim to assess
whether the management algorithm using data obtained
with a PiCCO system can improve clinical outcomes in
critically ill patients with septic shock or ARDS. We
hypothesize that a management algorithm based on the
PiCCO system will benefit critically ill patients in terms
of mortality, length of stay in an ICU and ventilation-
free days.
Methods
The study is designed as a prospective randomized con-
trolled multi-center trial in the ICUs of four tertiary
academic centers. These are mixed ICUs treating both
surgical and medical patients. The total number of beds
is 96. The study will last for a period of 2 years. The end
of the study is defined by the last follow-up of the last
enrolled patient. The study was approved by the ethics
committees of the participating institutions.
Patient selection
All patients admitted to a participating ICU during the
study period will be assessed for potential eligibility.
Patients with septic shock, ARDS or both are considered
to be eligible. Sepsis is defined as infection plus systemic
inflammatory response syndrome (SIRS). General vari-
ables are: (1) fever (>38.3°C) or hypothermia (core
temperature <36°C); (2) heart rate >90 min-1 or >2SD
above the normal value for age; (3) tachypnea; (4)
altered mental state; (5) significant edema or positive
fluid balance (>20 ml.kg-1 over 24 hrs); and (6) hypergly-
cemia (plasma glucose>140 mg.dl-1 in the absence of
diabetes). Inflammatory variables are: (1) leukocytosis
(white blood cell (WBC) count >12000 μL-1) or leuco-
penia (WBC count <4000 μL-1); (2) normal WBC count
with >10% immature forms; (3) plasma C-reactive pro-
tein >2SD above upper normal limit; and (4) plasma
procalcitonin >2SD above upper normal limit. Septic
shock is defined as a systolic blood pressure (SBP)
of <90 mm Hg or mean arterial pressure <70 mm Hg
or a SBP decrease >40 mm Hg despite adequate fluid re-
suscitation [16]. ARDS is defined according to the Berlin
definition [17]: (1) the onset should be within one week
of a known clinical insult or new/worsening respiratory
symptoms; (2) chest imaging shows bilateral opacities
that cannot be fully explained by effusions, lobar/lung
collapse or nodules; (3) respiratory failure is not fully
explained by cardiac failure or fluid overload. An ob-
jective assessment may be needed to exclude hydro-
static edema if no risk factor is present. ARDS is
divided into three mutually exclusive categories of mild
(200<PaO2/FiO2≤300 with positive end-expiratory
pressure (PEEP) or continuous positive airway pressure
(CPAP)≥5 cmH2O), moderate (100<PaO2/FiO2≤200
with PEEP ≥5 cmH2O) and severe (PaO2/FiO2≤100
with PEEP ≥5 cmH2O). The diagnosis of ARDS is made
by a specialist. Chest imaging (for example a chest
X-ray or computer tomography) is interpreted by a
radiologist. Patients are excluded if they met the exclu-
sion criteria: (1) younger than 18 years; (2) experienced
hemorrhagic shock; (3) are moribund, or informed con-
sent cannot be obtained; (4) contraindications to catheter
insertion, including overlying infection and arterial graft-
ing; (5) conditions likely to render PiCCO measurements
inaccurate, including intracardiac shunts, significant tri-
cuspid regurgitation, and cooling or rewarming [18-20].
Interventions
Experimental intervention
The PiCCO system is used within 2 hours of enroll-
ment. Central venous access is created for the injection
of cold water and measurement of central venous pres-
sure (CVP). The choice of type of central venous cath-
eter (CVC) and insertion site are at the discretion of the
treating physician. The preferred insertion site is the
jugular or subclavian position. We choose the femoral
position only when both of these sites are contraindi-
cated. A thermistor-tipped arterial catheter is inserted
into the femoral artery. Occasionally, the axillary artery
is used when femoral artery catheterization is contrain-
dicated [21]. Then 15 to 20 ml of normal saline at a
temperature <8°C is injected into the central vein, and
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various hemodynamic parameters can be obtained
through analysis of variations in blood temperature taken
by the temperature sensor of the arterial catheter. At least
three cold boluses are required for each calibration to
obtain an acceptable precision [22]. The calibration should
be performed at least every 8 hours, or following a major
change in a patient’s clinical condition [23]. To exclude
variations in blood volume and temperature caused by
continuous renal replacement therapy (CRRT), the cali-
bration will not be performed immediately after CRRT
is switched on or off, and the measurement can be
performed after the blood temperature reaches a steady
state (after two minutes) [24,25].
Fluid management aims to optimize the effective cir-
culating blood volume; vasoactive agents are used to
achieve a mean arterial pressure of at least 60 mmHg
when the volume status is optimal and extravascular
lung water is optimized to a negative fluid balance
[26,27]. If the intrathoracic blood volume index (ITBVI)
is less than 850 ml.m-2, a 500 ml bolus of hydroxyethyl
starch 130/0.4 (VoluvenW) is infused over 30 min aiming
for an ITBVI of 850 to 1000 ml.m-2. The bolus can be
repeated if the target is not reached. If the ITBVI
exceeds 1000 ml.m-2, nitroglycerin and/or dobutamine
are used based on mean arterial pressure (MAP) and
cardiac output (CI). If EVLWI ≥10 ml/kg, furosemide is
used. If MAP < 60 mmHg, norepinephrine is started at
0.05 μg.kg-1.min-1 with the option to increase at an incre-
ment of 0.05 μg.kg-1.min-1. If MAP > 100 mmHg, nitrogly-
cerin is given at the dose range of 0.5 to 3.0 μg.kg-1.min-1.
A red blood cell (RBC) transfusion is triggered when the
hemoglobin level Hb <7 g.dl-1, and if CI<2.5L.min-1.m-2
dobutamine is started at the dose of 2.5 μg.kg-1.min-1. The
target is to maintain central venous oxygen saturation
ScvO2>70% (Figure 1). Dynamic parameters for fluid re-
sponsiveness such as pulse pressure variation and stroke
volume variation were not included in the protocol
due to the requirement for positive ventilation, heavy
sedation or paralysis, and a regular cardiac rhythm. The
PiCCO system will be removed if the patient is clinically
stable for 48 hours as determined by attending physi-
cians. This system can be maintained for a maximum of
10 days. If catheter-related bloodstream infection
(CRBSI) is suspected, the central venous catheter will be
removed and sent for microbiological study, and the
catheter will be exchanged for a new one.
Control intervention
Patients in the control arm will not receive PiCCO
monitoring, but a central venous catheter is routinely
inserted. If the CVP is less than 8 mmHg, a 500 ml bolus
of hydroxyethyl starch 130/0.4 (VoluvenW) is infused over
30 min aiming to give a CVP of 8 to 12 mmHg. The bolus
can be repeated if the target is not reached. If the CVP
exceeds 12 mmHg, furosemide and/or nitroglycerin and/
or dobutamine are used at the discretion of the attending
physician. If MAP is less than 60 mmHg, norepinephrine
is started at 0.05 μg.kg-1.min-1 with the option to increase
at an increment of 0.05 μg.kg-1.min-1. If MAP > 100
mmHg, nitroglycerin is given at the dose range of 0.5 to
3.0 μg.kg-1.min-1. An RBC transfusion is triggered when
Hb<7 g.dl-1. ScvO2 is maintained >70% (Figure 2).
Study end point
The primary endpoint is 30-day mortality (death from
any cause before day 30).
Secondary outcome measures
ICU length of stay: Since the time of ICU discharge may
be affected by the availability of beds on a general ward,
we predefine the ICU length of stay as the day from ICU
admission to the day when the patient is ready for ICU
discharge. A patient is considered ready for discharge
when he or she is no longer in need for vital organ
support.
Days on mechanical ventilation: The criteria for termin-
ation of mechanical ventilation: a cooperative patient, re-
covery from primary disease, hemodynamically stable,
adequate and strong cough reflex, positive end-expiratory
pressure <5 cmH2O, pressure support <10 cmH2O and
the spontaneous breathing trial is successfully passed.
Ventilator-free days during 30-day period.
Days of vasoactive agent support: The sum of the
number of days with one or more vasoactive agents to
maintain a mean arterial pressure >60 mmHg.
Vasoactive-agent-free days in 30-day period.
ICU-free survival days during 30-day period.
Maximum sequential organ failure assessment (SOFA)
score during the first 7 days.
Data safety monitoring board
A Data Safety Monitoring Board chaired by the director
of the Department of Critical Care Medicine (XX) of
Jinhua Municipal Central Hospital, comprising experts
in clinical trials, biostatistics and intensive care, has
been established. The board will review data on patient
characteristics, compliance and study outcome in an
interim analysis (based on the availability of primary
outcomes for 350 patients). The study will be termi-
nated if one arm turns out to be harmful compared to
the other.
Adverse events were considered to be: hematoma,
pneumothorax, arterial emboli, catheter-relatedblood-
stream infection, hemorrhage, pseudoaneurysm or
arrhythmia.
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Sample size and statistical analysis
We assumed that the overall mortality at 30 days is 40%
[28,29]. A sample size was calculated to detect a 10%
difference in mortality at day 30 between the two groups
with a two-tailed test, a significance level of 5% and a
power of 80%. We plan to include a total of 708
subjects.
Baseline characteristics will be reported. The differ-
ence in 30-day mortality between the two groups will be
tested using a chi-square test and intention-to-treat
(ITT) analysis. Time-to-event variables including length
of stay in the ICU, duration of mechanical ventilation
and 30-day survival are compared between the two
groups using a log-rank test. Multivariate analysis (the
Cox proportional hazards regression model) is used to
estimate the hazard ratio adjusted for age, severity of
illness and disease category. Age and the APACHE II
score will be managed as continuous variables. Adverse
events will be reported according to the ITT protocol.
All tests are two sided and P<0.05 is considered to be
statistically significant. Statistical analysis will be per-
formed using Stata 11.0 (College Station, TX 77845,
USA).
Randomization
Eligible consecutive patients will be randomly assigned
to one of the treatment groups using randomization
sequences generated by computer and stratified accord-
ing to the primary diagnostic category on admission,
namely, septic shock and ARDS. Allocation conceal-
ment is achieved using sequentially numbered, sealed
opaque envelopes.
Blindness
The blinding of non-pharmacological treatment in our
study is complicated and costly. However, every effort is
Figure 1 Algorithm for hemodynamic management according to transpulmonary thermodilution-derived data. If ITBVI < 850 ml.m-2,
a 500 ml bolus of hydroxyethyl starch 130/0.4 (VoluvenW) was infused over 30 min aiming at an ITBVI of 850 to 1000 ml.m-2. The bolus can be
repeated if the target is not reached. If ITBVI >1000 ml.m-2, nitroglycerin and/or dobutamine are used based on MAP and CI. If EVLWI ≥10 ml/kg,
furosemide is used. If MAP < 60 mmHg, norepinephrine is started at 0.05 μg.kg-1.min-1 with the option to increase at an increment of
0.05 μg.kg-1.min-1. If MAP > 100 mmHg, nitroglycerin is given at the dose range of 0.5 to 3.0 μg.kg-1.min-1. RBC transfusion is triggered when
Hb <7 g.dl-1, and if CI <2.5L.min-1.m-2 dobutamine is started at the dose of 2.5 μg.kg-1.min-1. The target is to maintain ScvO2>70%. CI, cardiac
output; EVLWI, extravascular lung water index; Hb, hemoglobin level; ITBVI, intrathoracic blood volume index; MAP, mean arterial pressure; RBC,
red blood cell; ScvO2, central venous oxygen saturation.
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made to mask the study researchers and participants
[30]. We use the same electrocardiogram (ECG) moni-
tor (Philips IntelliVue Patient Monitor with a PiCCO
module) for both intervention and control arms. A
sham procedure of injecting cold water is performed for
patients in the control arm. Investigators who collect
baseline characteristics and follow-up participants are
blinded to patient assignment.
Ethical aspects
The study has been approved by the ethics committees
of Jinhua Municipal Central Hospital, the Traditional
Chinese Medical Hospital of Jinhua City, Dongyang
People’s Hospital and the First People’s Hospital of
Yongkang City. The research will be explained in detail
to the patient or the next-of-kin prior to enrollment.
The explanation will include the type and method of the
study, the complications of PiCCO monitoring and the
potential benefit or harm of the intervention. Written
informed consent will be obtained from the patients or
their surrogates. The patient or surrogate can withdraw
from the study at any time.
The study is conducted according to the Declaration
of Helsinki.
Discussion
Fluid therapy is an art in the treatment of critically ill
patients. To facilitate treatment and improve patient
outcomes, every effort has been made to enhance the
technology used for measuring relevant physiological
parameters. These parameters allow us to better under-
stand the underlying mechanisms of certain disorders.
For instance, in septic shock, hemodynamic monitoring
will typically present a low systemic vascular resistance
and high or normal-high cardiac output. Intuitively, an
understanding of pathophysiological mechanisms will
eventually translate into improvements in clinical out-
comes. Pulmonary artery catheters (PACs) have been
Figure 2 Algorithm for hemodynamic management in the control arm. If CVP< 8 mmHg, a 500 ml bolus of hydroxyethyl starch 130/0.4
(VoluvenW) was infused over 30 min aiming at a CVP of 8 to 12 mmHg. The bolus can be repeated if the target is not reached. If CVP >12 mmHg,
furosemide and/or nitroglycerin and/or dobutamine are used at the discretion of the attending physician. If MAP < 60 mmHg, norepinephrine is started
at 0.05 μg.kg-1.min-1 with the option to increase at an increment of 0.05 μg.kg-1.min-1. If MAP > 100 mmHg, nitroglycerin is given at the dose range of
0.5 to 3.0 μg.kg-1.min-1. An RBC transfusion is triggered when Hb<7 g.dl-1. ScvO2 is maintained >70%. CVP, central venous pressure; Hb, hemoglobin; RBC,
red blood cell; ScvO2, central venous oxygen saturation.
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widely used for several decades only because they
allow clinicians to get more information regarding
hemodynamic status, but without clinical evidence of
improved outcomes. In response to this lack of evi-
dence, several randomized controlled trials have been
conducted to test the usefulness of PACs in improving
clinical outcomes [31-33]. Unfortunately, all these trials
consistently show that PACs do no better than controls
regarding patient outcomes, but they increase medical
costs significantly. These disappointing results have
tempered the enthusiasm for PACs, and a survey
showed that the use of PACs decreased by 65% during
recent decades [34-36].
However, the failure of PACs in improving clinical
outcomes does not mean that the measurement of
hemodynamic parameters is useless. On the contrary, it
reflects the limited understanding of the complex
hemodynamic characteristics in critically ill patients.
With the declining use of PACs, there is an increasing
number of alternatives for hemodynamic monitoring.
The PiCCO system is one such alternative, which inte-
grates a wide series of both static and dynamic
hemodynamic parameters through a combination of
TPTD and pulse contour analysis. The PiCCO system
has several advantages over a PAC. First, PiCCO is less
invasive than a PAC, so that the severe complications
attributable to PACs, such as a pulmonary embolism,
pulmonary artery rupture and arrhythmia, are less likely
to occur [37]. Furthermore, the arterial canalization
required for PiCCO is safe and no significant adverse
events for the usually used femoral site have been
demonstrated [38,39]. Second, the PiCCO system has
the unique ability to measure global end diastolic vol-
ume (GEDV) and EVLW. Multiple studies have demon-
strated the superiority of GEDV over filling pressures
(for example the central venous pressure and pulmon-
ary artery wedge pressure) in estimating cardiac preload
[40-42]. EVLWI is a quantitative assessment of pulmon-
ary edema, which has been shown to be associated with
clinical outcomes, and EVLW-directed fluid therapy
may be potentially useful in improving patient clinical
outcomes, such as the duration of mechanical ventila-
tion, length of stay in ICU and mortality [43-45]. Third,
PiCCO allows continuous measurement of cardiac
output, which is potentially useful given the rapidly
changing hemodynamic conditions in critically ill
patients. Fourth, the PiCCO system is an ‘all inclusive’
hemodynamic monitor, which integrates an array of
parameters. Adjusting fluid parameters by considering
all aspects of cardiac performance may confer better
clinical outcomes than using a single hemodynamic
parameter [4]. However, compared with a PAC, the
PiCCO device cannot monitor pulmonary artery (PA)
pressure, pulmonary artery occlusion pressure (PAOP)
and mixed venous oxygen saturation. Filling pressures,
as previously mentioned, are not an accurate parameter
of cardiac preload. Thus, PAOP measurements are not
mandatory and can be replaced by GEDV to estimate
cardiac preload. Furthermore, although not numerically
exchangeable, mixed venous oxygen saturation can be
approximated by central venous oxygenation saturation
[46-48]. Therefore, based on current knowledge, the
PiCCO system appears to be superior to the PAC in
hemodynamic monitoring of critically ill patients.
The current study aims to investigate the usefulness
of the PiCCO system in improving outcomes for patient
with ARDS and septic shock. We believe that this
randomized controlled trial will provide new evidence
for fluid management in critical care settings.
Trial status
The trial is currently recruiting study subjects.
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